3月6日 - ** 远程医疗公司Hims & Hers HIMS.N的股价盘前下跌9%，至37.2美元。
** 美国联邦法官 (link) 驳回了一项禁令，该禁令本可允许复方药店继续在美国生产礼来LLY.N的流行减肥药Zepbound
** 外包设施协会于 10 月份对 FDA 将该药物从短缺名单中删除的决定提起诉讼，称该药物仍然供不应求。
** HIMS销售诺和诺德公司NOVOb.CO的Wegovy和Ozempic（化学名称为semaglutide）的复方制剂。
** 花旗银行（Citi）表示："这一裁决'直接影响到semaglutide悬而未决的案件，我们预计FDA也会支持这一案件'。
** HIMS 的股价在过去 12 个月里上涨了近两倍
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.